Salarius Pharmaceuticals Inc (SLRX)

SLRX...$1.20...🥳

SLRX........................................................a/h

$SLRX: popper....... $1.20

whats the deally yo

GO $SLRX

SLRX, new 52 week low

SLRX: NASDAQ now like the old Pre-Columbian OTC days!!!!

halt.. don't move

SLRX..........................https://stockcharts.com/h-sc/ui?s=SLRX&p=W&b=5&g=0&id=p86431144783

SLRX: On the Moon already, behind that MERGER news today, but hardly any iHub POSTS about it; maybe because merely one of those @SAGE-like 'BUY-OUTS' at a specific PRICE?? So it doesn't soar beyond that?? Just a stupid GUESS.)

$1.85

$1.79 low floater needs a little volume and off it goes $3.9-$3.73 target 

 approval of the issuance of additional shares by our stockholders in accordance with the applicable stock exchange rules or (ii) the average price paid for all shares of common stock issued under the Purchase Agreement (including both Purchase Shares and Commitment Shares) is equal to or greater than $1.528, which is a price equal to the lower of (A) the Nasdaq Official Closing Price immediately preceding the execution of the Purchase Agreement and (B) the average Nasdaq Official Closing

....This prospectus relates to the potential resale from time to time by C/M Capital Master Fund, LP, or the Selling Stockholder, of up to 6,733,334 shares of common stock, par value $0.0001 per share, or common stock. The shares of common stock to which this prospectus relates consists of shares that have been or may be issued by us to the Selling Stockholder pursuant to a Securities Purchase Agreement, dated as of December 12, 2024, by and between us and the Selling Stockholder, ...

This prospectus relates to the potential resale from time to time by C/M Capital Master Fund, LP, or the Selling Stockholder, of up to 6,733,334 shares of common stock, par value $0.0001 per share, or common stock. The shares of common stock to which this prospectus relates consists of shares that have been or may be issued by us to the Selling Stockholder pursuant to a Securities Purchase Agreement, dated as of December 12, 2024, by and between us and the Selling Stockholder, or the Purchase Agreement, establishing an equity line of credit, or the Equity Financing. Such shares of our common stock include (i) up to 6,666,667 shares of common stock, or the Purchase Shares, that we may elect, in our sole discretion, subject to the restrictions and satisfaction of the conditions in the Purchase Agreement, to issue and sell to the Selling Stockholder, from time to time from and after the Commencement Date (as defined below) under the Purchase Agreement, and subject to applicable stock exchange rules (assuming the shares are sold at a price of $1.50 per share) and (ii) up to 66,667 shares of common stock, or the Commitment Shares, that may be issued to the Selling Stockholder in connection with related issuances and sales of Purchase Shares as consideration for the Selling Stockholder’s execution and delivery of the Purchase Agreement. The actual number of shares of our common stock issuable will vary depending on the then-current market price of shares of our common stock sold to the Selling Stockholder under the Purchase Agreement, but will not exceed the number set forth in the preceding sentences unless we file an additional registration statement under the Securities Act of 1933, as amended, or the Securities Act, with the Securities Exchange Commission, or the SEC, and we obtain the approval of the issuance of shares of common stock by our stockholders in accordance with the applicable stock exchange rules. Under the applicable rules of The Nasdaq Stock Market LLC, or Nasdaq, in no event may we issue to the Selling Stockholder shares of our common stock representing more than 19.99% of the total number of shares of common stock outstanding as of the date of the Purchase Agreement, unless (i) we obtain the approval of the issuance of such shares by our stockholders in accordance with the applicable stock exchange rules or (ii) the average price paid for all shares of common stock issued under the Purchase Agreement (including both Purchase Shares and Commitment Shares) is equal to or greater than $1.528, which is a price equal to the lower of (A) the Nasdaq Official Closing Price immediately preceding the execution of the Purchase Agreement and (B) the average Nasdaq Official Closing Price of our common stock for the five trading days immediately preceding the execution of the Purchase Agreement, as calculated in accordance with the rules of Nasdaq, such that the sales of such common stock to the Selling Stockholder would not count toward such limit because they are “at market” under applicable stock exchange rules. See “The Committed Equity Financing” for a description of the Purchase Agreement and “Selling Stockholder” for additional information regarding the Selling Stockholder.We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of the shares of our common stock by the Selling Stockholder. Additionally, we will not receive any proceeds from the issuance or sale of any Commitment Shares. However, we may receive up to $10.0 million in aggregate gross 
proceeds from the sale of the shares of common stock to the Selling Stockholder under the Purchase Agreement, from time to time in our discretion, subject to the restrictions and satisfaction of the conditions in the Purchase Agreement, after the date the registration statement that includes this prospectus is declared effective and after satisfaction of other conditions in the Purchase Agreement. The actual proceeds from the Selling Stockholder may be less than this amount depending on the number of shares of our common stock sold and the price at which the shares of our common stock are sold.This prospectus provides you with a general description of such securities and the general manner in which the Selling Stockholder may offer or sell the securities. More specific terms of any securities that the Selling Stockholder may offer or sell may be provided in a prospectus supplement that describes, among other things, the specific amounts and prices of the securities being offered and the terms of the offering. The prospectus supplement may also add, update or change information contained in this prospectus.The Selling Stockholder may offer, sell or distribute all or a portion of the shares of our common stock acquired under the Purchase Agreement and hereby registered publicly or through private transactions at prevailing market prices or at negotiated prices. We will bear all costs, expenses and fees in connection with the registration of the shares of our common stock, including with regard to compliance with state securities or “blue sky” laws. The timing and amount of any sales are within the sole discretion of the Selling Stockholder. The Selling Stockholder is an underwriter under the Securities Act with respect to the resale of shares held by it. Although the Selling Stockholder is obligated to purchase shares of our common stock under the terms and subject to the conditions and limitations of the Purchase Agreement to the extent we choose to sell such shares of our common stock to it (subject to certain conditions), there can be no assurances that we will choose to sell any shares of our common stock to the Selling Stockholder, or that the Selling Stockholder will sell any or all of the shares of our common stock, if any, purchased under the Purchase Agreement pursuant to this prospectus. The Selling Stockholder will bear all commissions and discounts, if any, attributable to its sale of shares of our common stock. See “Plan of Distribution.”You should read this prospectus and any prospectus supplement or amendment carefully before you invest in our securities.Our common stock is listed on The Nasdaq Capital Market under the symbol “SLRX.” On December 12, 2024, the last reported sale price of our common stock on The Nasdaq Capital Market was $1.44 per share.We are a “smaller reporting company” as defined under the federal securities laws and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and the documents incorporated by reference herein, and may elect to comply with reduced public company reporting requirements in future filings. Please see “Prospectus Summary ? Implications of Being a Smaller Reporting Company.”

slrx...............................https://stockcharts.com/h-sc/ui?s=slrx&p=W&b=5&g=0&id=p86431144783

Ready 

Boom boom ready for liftoff again

SLRX.......................https://stockcharts.com/h-sc/ui?s=SLRX&p=W&b=5&g=0&id=p86431144783

SLRX......................................https://stockcharts.com/h-sc/ui?s=SLRX&p=W&b=5&g=0&id=p86431144783

I think AH. I was on the USS QNRX today and it was rising Beautifully, It stated a Halt to Upside so waited and the walls came tumbling
down. what a play action fake.

SLRX: Well, maybe a little MUSIC???

SLRX: And THERE it goes!!!

Reverse split in June looks primed for another pump. Buy a few for the quick upcoming pump and dump show

SLRX..................................https://stockcharts.com/h-sc/ui?s=SLRX&p=W&b=5&g=0&id=p86431144783

MOON

SLRX 10Q due AUGUST 5

SLRX 500K Float FDA News Coming Watch for a WINT Type move to the upside trading under cash with FDA News Imment Trading under Cash with over 7$ per share

SLRX.......................................................https://stockcharts.com/h-sc/ui?s=SLRX&p=W&b=5&g=0&id=p86431144783

https://dilutiontracker.com/app/search/SLRX?a=dbb88c

Brazen manipulation, computer generated wash trading. The O/S has turned over 100X's today. Don't get trapped with grossly overpriced stock.

Yikes

SLRX.........................................https://stockcharts.com/h-sc/ui?s=SLRX&p=W&b=5&g=0&id=p86431144783

SLRX..................................https://stockcharts.com/h-sc/ui?s=SLRX&p=W&b=5&g=0&id=p86431144783

SLRX new 52 week low

chart looks ready

3.40s

SLRX new 52 week low

SLRX 1 for 8 Monday 6/17

SLRX new 52 lo

SLRX new 52 week low

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders,announced 1/5/23,next greatest cure for cancer is possible>targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces that on December 27, 2022 the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,535,603, titled “Deuterium-enriched Piperidinonyl-oxoisoindolinyl Acetamides and Methods of Treating Medical Disorders Using Same.” The issued claims cover the composition of matter for novel molecular glue degraders including Salarius’ preclinical cereblon-binding compound, SP-3204, through September 2037.
Targeted protein degradation (TPD) takes advantage of the body’s own degradation system to promote the selective elimination of disease-causing proteins. The newly issued patent is based on the molecular glue eragidomide (CC-90009) that is known to target the degradation of GSPT1, a protein that is highly expressed in numerous cancers, including hematologic and solid tumors.

got the bounce off 200ma @ $3.30 ,float rotated 1x in 1 hr wow!!!

zero borrow,no shares to short,gap filled, summit speaking 26th

2m float,target $70.00,institution 17%,vol 4Xs ave,#1on my scanner,world looking at it now

nasdaq promo out,thinking about buying!!!

Top picks here would be $GMER $NILE $SNPX. Best reward to risk plays. Honorable mentions, $NBRI $PGAS $NXGT
I'm done posting on this board. But it's been nice communicating with you. I'm vested in all the above so maybe we'll continue on any of the other boards.
Good luck to you.

the return of money in the OTC due to the rise in inflation is interesting.
I am currently exposed on XBIO Xenetic Biosciences at Nasdaq.
I have a small position on a very risky OTC stock.
(SMFX) SAM TRADE. has an ongoing process for an undeclared license in Singapore., but if it resolves to a small fine, it could take off ....

p.s.
I will wait NVDA in the $ 140-150 area before a buy ..

They may have started with good intentions but only a very few small bios ever materialize into something of real substance. Most are just ATM plays, banking off of hopeful and or naive investors. Took me a long time to see the forest from the trees. Better late than never. I monitor a lot of stocks and when I see weak bios issuing ATM I make a point to never re enter. A private placement is the best case scenario. They don't deserve my wallet or attentions thereafter. Eventually, with the market showing no signs of reversing for years to come, if at all, most will be delisted or bk. You can only play the investors to a certain point. With investors running for the exits, they'll be soon finding themselves with shut doors, as most won't be able to stay off creditors or debt liabilities. Good.

At this point in the pre hyper inflation recession period, I'm seeing an early return of monies into the OTC sector. Fwiw, here's a decent article on a few reward to risk plays that actually might produce some stellar returns. I know I can use it. Ugh...

https://insiderfinancial.com/4-otc-stocks-to-boost-your-portfolio-cybl-dpls-gmer-lclp/183146/

Glta

you are 100% right ....
they are management to be arrested immediately, sucking shareholders' money on the hope of a cure. incompetent and thieves !!!

I've monitored this after making some coin a long time ago. Since then, been a dog and rightly so. Seeing a lot of small cap bios that have issued ATM at beaten down low stock prices. Why? Because they inherently have nothing of value to offer except sell shares, get a paycheck, and continue their facade. It's happening on a lot of these plays in this sector sad to say. Most should be delisted and or bought out primarily for the NOLS write offs to big pharma. Most of these dogs will and should fail. Anybody that knows anyone with cancer, knows that very little has changed beyond chemo and radiation. Despite all the monies supposedly spent on advancements, treatments haven't changed. Immunotherapy treatments are starting to gain treatment protocols, and experimental last ditch efforts on stem cells, but the majority is still chemo and radiation.
Anyways, I've sworn off these dead end oncology small bios, as little if any return on investments other than disappointments. I especially write off any that issue ATM at this sub $1 low of years prices. Looking at a reverse split followed by wash rinse and repeats. Corporate should be ashamed of themselves for terrible fiduciary management of shareholders monies. But they don't care. So vote with your wallet and find real companies with product and revenues. Let these dogs die as they should.
Glta